Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Inicie sesión o únase ahora para utilizar esta función

Recruiting

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome - IM039-004

Actualizada: 6 abril, 2021   |   ClinicalTrials.gov

Imprimir Resumen

¿ESTÁ CONSIDERANDO PARTICIPAR EN ESTE ESTUDIO?
Imprima esta página y la guía del estudio para poder hablar mejor con su médico.
Use la guía de estudios para explorar el proceso de participación en un estudio clínico. Comprenda qué factores clave debe considerar antes de decidirse y piense preguntas para hacerle a su equipo de atención médica.

Detalles del estudio

  • Phase 1

    Fase

  • Géneros

  • 18-65

    Rango de edad

  • 1

    Ubicación (es)

  • Recruiting

Opciones de tratamiento

Brazos del estudio
INTERVENCIÓN ASIGNADA
Experimental: Part A SAD Dose 1
Biological: BMS-986325
Experimental: Part A SAD Dose 10
Experimental: Part A SAD Dose 11 (Optional Arm)
Experimental: Part A SAD Dose 2
Other: Placebo
Experimental: Part A SAD Dose 3
Biological: BMS-986325
Experimental: Part A SAD Dose 4
Other: Placebo
Experimental: Part A SAD Dose 5
Biological: BMS-986325
Experimental: Part A SAD Dose 6
Other: Placebo
Experimental: Part A SAD Dose 7
Experimental: Part A SAD Dose 8
Experimental: Part A SAD Dose 9
Placebo Comparator: Part A SAD Placebo 1
Placebo Comparator: Part A SAD Placebo 2
Experimental: Part B MAD Dose 1
Experimental: Part B MAD Dose 2
Experimental: Part B MAD Dose 3
Placebo Comparator: Part B MAD Placebo
Experimental: Part C pSS Dose 1
Experimental: Part C pSS Dose 2
Experimental: Part C pSS Dose 3 (Optional Arm)
Placebo Comparator: Part C pSS Placebo

Criterios clave de elegibilidad

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - BMI: 18.0 to 30.0 kg/m2, weight: ≥ 50 kg at screening - Must agree to follow specific methods of contraception, if applicable Healthy Participants (Part A and Part B) - Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination (PE), electrocardiograms (ECGs), and clinical laboratory determinations - Males and Females, ages 18, or local age of majority, to 50 years, inclusive at screening Participants with Sjögren's Syndrome (Part C) - Sjögren's syndrome in the absence of another immune-mediated disease or rheumatologic condition based on the 2016 American College of Rheumatology-European League Against Rheumatism (EULAR) Classification Criteria for primary Sjögren's syndrome (pSS) - Seropositive for anti-Sjögren's syndrome antigen A antibody - Males and females, ages 18, or local age of majority, to 65 years, inclusive at screening Exclusion Criteria: - Woman who are pregnant or breastfeeding - Inability to tolerate venipuncture and/or inadequate venous access Healthy Participants (Part A and Part B) - Any significant acute or chronic medical illness - Any other significant medical, psychiatric, and/or social reason as determined by the investigator Participants with Sjögren's Syndrome (Part C) - Systemic immune-mediated disease other than pSS, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), mixed connective tissue disease, or systemic sclerosis, that can better explain the majority of the symptoms (i.e., secondary Sjögren's syndrome) - Another immune-mediated disease or inflammatory condition that could interfere with assessment of response of pSS to therapy (e.g., immunoglobulin G4 (IgG4)-related disease, systemic sclerosis, inflammatory bowel disease, gout) - Any other medical condition associated with sicca syndrome (e.g., history of head and neck radiation treatment, diabetes mellitus, sarcoidosis, chronic graft-versus host disease), participants with sicca symptoms secondary to ongoing medication use based on the investigator's assessment Other protocol-defined inclusion/exclusion criteria apply

Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica

¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 - Llame 855-907-3286 o Envíenos un correo electrónico

¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 -
Llame 855-907-3286 o Envíenos un correo electrónico